MIT study suggests caution on new anti-obesity drug in kids

15 07 2008

Anti-obesity drugs that work by blocking brain molecules similar to those in marijuana could also interfere with neural development in young children, according to a new study from MIT’s Picower Institute for Learning and Memory.

Marijuana is known to be an appetite stimulant, and a new class of anti-obesity drugs—such as rimonabant (trade name Acomplia) developed by Sanofi-Aventis and awaiting approval for use in the United States—work by blocking brain receptors that bind to marijuana and other cannabinoids.

Marijuana, derived from the plant Cannabis sativa, contains special active compounds that are referred to collectively as cannabinoids. But other cannabinoids (endocannabinoids) are generated naturally inside the body.

The MIT study, which was done in mice, found that blocking cannabinoid receptors could also suppress the adaptive rewiring of the brain necessary for neural development in children. The work is reported in the May 8 issue of Neuron.

“Our finding of a profound disruption of cortical plasticity in juvenile mice suggests caution is advised in the use of such compounds in children,” wrote lead author Mark F. Bear, director of the Picower Institute and Picower Professor of Neuroscience.

The researchers investigated plasticity—the brain’s ability to change in response to experience—by temporarily depriving newborn mice of vision in one eye soon after birth. This well-known experiment induces a long-lasting loss of synapses that causes blindness in the covered eye, while synapses shift to the uncovered eye. How and where this synaptic shift occurs in the primary visual cortex has remained controversial.

Understanding the mechanism behind this phenomenon is key because the same brain mechanisms are used for normal development and may go awry in conditions that cause developmental delays in humans, and may reappear in old age and contribute to synaptic loss during Alzheimer’s disease, Bear said.

In mice, the MIT researchers found, even one day of deprivation from one eye starts the shift to dominance of the uncovered eye. But injecting the mice with a cannabinoid receptor blocker halted the shift in certain brain regions, indicating that cannabinoids play a key role in early synaptic development.

Blocking cannabinoids receptors could thwart this developmental process, the researchers said.

This work is supported by the National Eye Institute and the National Institute of Mental Health.



One response

22 07 2008

Risk assessment seems to be much more relaxed when considering patented drugs. An anti-obesity drug being developed for children blocks the anandamide receptors in the brain, in an effort to create an ‘anti-muchies’ effect.

Joking aside, it’s amazing that it is acceptable to tamper with the neurochemistry of children in order to sell an anti-fat drug, yet the sanctity of those exact same brain receptors is a reason to lock up adults who choose cannabis over alcohol. It’s not clear what relationship anandamide and its receptors have with psychosis, but it’s more than likely that they’re a part of the body’s defence against mental illness.

The evil smoke of cannabis might have a chance of negatively affecting those receptors, but chemically nullifying them is fine.

It’s a similar hypocrisy to that of citing the delicate neurochemistry of children as an excuse to keep cannabis illegal at the same time as prescribing antidepressants (which are specifically designed to change neurochemistry, with side-effects we barely understand) to the same children.

Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: